Inhalation Drug Delivery Articles

  1. GenAI: The Muscle Behind Strong Regulatory Intelligence For Combination Products 3/2/2026

    In this article, combination product consultant Doug Mead provides the rationale and offers guidance for using GenAI tools to search regulatory databases. He shows the benefits for biopharma developers of conducting “precedent research” into previous regulatory pathways and results for similar or related drug delivery product submissions. 

  2. Regulatory Precedents For Drug Delivery: Uncovering Clues To Successful Submissions 3/2/2026

    In this article, Chief Editor Tom von Gunden considers the need for and benefit of conducting AI-based research into regulatory precedents for drug delivery submissions and approvals. He consults combination products consultant Doug Mead on best practices in bolstering regulatory intelligence and regulatory approval success by way of advanced search methods. 

  3. Overcoming Lung Tumor Barriers: Nanoparticle Delivery Strategies For Pulmonary Cancers 2/20/2026

    Solid lung tumors have a complex tumor microenvironment that creates barriers to drug delivery. Nanoparticle therapies can overcome these challenges.

  4. 4 Opportunities For Advancing Drug Delivery 2/3/2026

    In this article, Fran DeGrazio identifies four prime opportunities for drug delivery developers to move the dial of innovation into 2026 and beyond. These avenues for advancement include diagnostics, patient tolerability, microdosing, and analytical methodologies. 

  5. Conducting A Medical Device Stability Study: A Practical Guide 1/7/2026

    Stability studies measure how medical devices respond to environmental stresses such as temperature, humidity, light, and time. Let's take a closer look at designing and conducting a stability study.

  6. Nanotechnology Drug Delivery: A Market Overview 1/6/2026

    New market research reveals the scientific, geopolitical, and business trends driving growth in the nanotechnology drug delivery market.

  7. Combination: The Drug Delivery Word Of The Year For 2026 12/30/2025

    In this article, Chief Editor Tom von Gunden explains why he sees 2026 as the year combination products and therapies become fully central to drug and biologics product development, delivery, and regulatory. He points to personalized medicine and patient self-administration as key factors shaping his view of the drug delivery landscape.

  8. Electronic Drug Delivery Devices Market: Advancing Smart, Connected Healthcare 12/19/2025

    What is factoring into market growth for electronic drug delivery devices and why? New market research shares key insights.

  9. Regulating For Patient Safety And Success With Combination Products 12/16/2025

    At the AFDO/RAPS Combination Products Summit 2025, a notable focus emerged around approaches to risk assessment and human factors studies. In this article, Chief Editor Tom von Gunden offers his appreciation for the biopharma industry’s consideration of patient usability and safety in the development and regulation of combination products and other drug delivery devices. 

  10. Drug Delivery Trends From 2025: Top 4 For Momentum Gains In 2026 12/2/2025

    In this article, Fran DeGrazio identifies four notable trends in drug delivery that gained momentum in 2025 and, she predicts, will continue to do so in 2026 and beyond. They are digitalization, sustainability, patient centricity, and the advanced delivery of complex biopharmaceuticals.